Sabrina S. Burgener, Mathias Baumann, Paola Basilico, Eileen Remold-O'Donnell, Ivo P. Touw and Charaf Benarafa*

Myeloid conditional deletion and transgenic models reveal a threshold for the neutrophil survival factor Serpinb1

DOI 10.1515/hsz-2016-0132
Received February 2, 2016; accepted April 20, 2016; previously published online April 22, 2016

Abstract: Serpinb1 is an inhibitor of neutrophil granule serine proteases cathepsin G, proteinase-3 and elastase. One of its core physiological functions is to protect neutrophils from granule protease-mediated cell death. Mice lacking Serpinb1a (Sb1a⁻/⁻), its mouse ortholog, have reduced bone marrow neutrophil numbers due to cell death mediated by cathepsin G and the mice show increased susceptibility to lung infections. Here, we show that conditional deletion of Serpinb1a using the Lyz2-cre and Cebpa-cre knock-in mice effectively leads to recombination-mediated deletion in neutrophils but protein-null neutrophils were only obtained using the latter recombinase-expressing strain. Absence of Serpinb1a protein in neutrophils caused neutropenia and increased granule permeabilization-induced cell death. We then generated transgenic mice expressing human Serpinb1 in neutrophils under the human MRP8 (S100A8) promoter. Serpinb1a expression levels in founder lines correlated positively with increased neutrophil survival when crossed with Sb1a⁻/⁻ mice, which had their defective neutrophil phenotype rescued in the higher expressing transgenic line. Using new conditional and transgenic mouse models, our study demonstrates the presence of a relatively low Serpinb1a protein threshold in neutrophils that is required for sustained survival. These models will also be helpful in delineating recently described functions of Serpinb1 in metabolism and cancer.

Keywords: cell death; cre; serine protease; serpin.

Introduction

Neutrophils (PMNs) are granulocytes with central functions in inflammatory disease and in innate immunity against microbes (Kruger et al., 2015). Because isolated PMNs are short-lived, they are poorly amenable to in vitro manipulation such as RNA interference and transfection. The use of genetic engineering in mice has thus been helpful in delineating molecular pathways in PMN homeostasis and functions. With this approach, we and others have shown that PMN survival in vivo depends in part on inhibition of granule serine proteases by Serpinb1a (Benarafa et al., 2011; Baumann et al., 2013; Loison et al., 2014). Human SERPINB1 and its mouse homolog Serpinb1a are intracellular inhibitors of neutrophil serine proteases cathepsin G, proteinase-3 and elastase (Cooley et al., 2001; Benarafa et al., 2002). Serpinb1a-deficient mice (Sb1a⁻/⁻) present a profound reduction in PMN survival, leading to a neutropenia in the bone marrow (BM) in steady state conditions as well as in the periphery during infection (Benarafa et al., 2007, 2011). Serpinb1a is expressed broadly in all leukocytes including hematopoietic stem cells (HSCs) but also at high levels in many organs such as lungs, liver, pancreas and prostate (Benarafa et al., 2002). There is an emerging literature correlating variations of Serpinb1 expression with progression of various types of cancers and inflammatory diseases (Ashida et al., 2004; Popova et al., 2006; Yasumatsu et al., 2006; Tseng et al., 2009; Naito et al., 2010; Cui et al., 2014; Zhao et al., 2014; Huasong et al., 2015; Sheng et al., 2015; El Ouaamari et al., 2016). Therefore, additional models to investigate specific functions of this serpin in vivo are needed. Here, we developed and validated tools to conditionally delete Serpinb1a using cre-loxP technology in myeloid cells and,
Sac-F/-re/-/-(Sb1a) almost complete cre-mediated recombination of the BM of Lyz2cre mice, however, absolute numbers and percentage of PMNs in and, as expected, no recombination in B cells (Figure 2A).

locus in PMNs, partial recombination in myelocytes Lyz2cre promoter (Lyz2 binase from the endogenous Sb1a to those of Sb1a+/+). Serpinb1a was previously shown to be an effective common used knock-in mice expressing the cre recombinase in ES cells. Deletion of exon 7, which encodes the reactive center loop of the serpin, was previously shown to be an effective null allele (Benarafa et al., 2007).

inversely, we generated a transgenic mouse expressing human Serpinb1 (hSerpinb1) in PMNs that rescues the BM neutropenia of Sb1a−/− mice.

Results

Lyz2-driven cre recombination of Serpinb1a floxed allele in neutrophils

We have previously targeted Serpinb1a in embryonic stem (ES) cells using a 3-loxP strategy (Benarafa, 2011). Transient transfection of an ES cell clone with a cre expressing plasmid allowed removal of the selection cassette and the generation of ES cell clones with a constitutive deleted allele as well as clones with a conditional allele (Figure 1). The characterization of constitutive Sb1a−/− mice derivied from ES cells carrying a deleted allele was described previously (Benarafa et al., 2007, 2011). To investigate the phenotype of mice lacking Serpinb1a principally in myeloid cells, conditional Sb1a−/− mice were interbred with the commonly used knock-in mice expressing the cre recombinase from the endogenous Lyz2 (also known as LysM) promoter (Lyz2cre) (Clausen et al., 1999). PCR analysis of genomic DNA of sorted BM leukocyte subsets confirmed almost complete cre-mediated recombination of the Serpinb1a locus in PMNs, partial recombination in myelocytes and, as expected, no recombination in B cells (Figure 2A).

However, absolute numbers and percentage of PMNs in the BM of Lyz2cre(Sb1a−/−) mice were normal and equivalent to those of Sb1a+/+, Sb1a−/− and Lyz2−/−Sb1a−/− mice (Figure 2B), whereas Sb1a−/− mice had reduced PMN numbers as we previously reported (Benarafa et al., 2011; Baumann et al., 2013). As expected, B cell numbers were not significantly different between all genotypes (Figure 2C). Western blot analysis of sorted BM cells revealed that Serpinb1a protein was still detectable in PMN lysates of Lyz2cre Sb1a−/− mice at levels comparable to those of Sb1a+/+ mice (Figure 2D).

Figure 1: Generation of Serpinb1a−/− mice.

Shown at the top is the targeted Serpinb1a locus with 3-loxP sites (black triangles) in ES cells. Cre recombinase in ES cells (indicated by white arrows) generated two new alleles: either a floxed (Serpinb1a weight) allele or a deleted (Serpinb1a weight) allele. In vivo recombination (red arrow) of a floxed allele in Serpinb1a−/− (Sb1a−/−) mice is expected to generate a deleted allele in cell lineages expressing cre. Deletion of exon 7, which encodes the reactive center loop of the serpin, was previously shown to be an effective null allele (Benarafa et al., 2007).

Figure 2: Lyz2cre deletion of Serpinb1a−/−.

(A) PCR analysis of genomic DNA isolated from flow cytometry sorted BM cells isolated from Lyz2cre(Serpinb1a−/−) mice. Arrows indicate expected size of PCR products for Sb1a alleles (deleted 500bp; floxed 410bp; WT 250bp) as indicated by ear biopsy standard samples. Total number and percentage of BM PMN (B) and B cell (C). BM and blood cell numbers and percentages were analyzed by Mann-Whitney U-test (**p<0.001). (D) Western blot analysis of Serpinb1a and β-actin of flow-sorted BM PMNs.

Brought to you by | Harvard University
Authenticated
Download Date | 10/27/16 10:28 PM
These findings demonstrate that \(\text{Lyz}^2\)-driven deletion of the Serpinb1a locus does not produce PMNs defective in Serpinb1a protein despite efficient DNA recombination in PMNs.

**Cebpa-driven cre recombination of Serpinb1a floxed allele in neutrophils**

To evaluate an alternative model, \(Sb1a^{F/F}\) mice were intercrossed with mice expressing the cre recombinase from endogenous CCAAT/enhancer binding protein \(\alpha\) (C/EBP\(\alpha\)) promoter, which drives expression at an earlier developmental stage in myelopoiesis than Lzm2 (Wölfler et al., 2010). Efficient deletion of the floxed allele was observed in PMNs, myelocytes and monocytes but not in B cells (Figure 3A). Western blot analysis also confirmed absence of Serpinb1a protein in sorted PMN lysates of Cebpa\(^{+/+}\)Sb1a\(^{F/F}\) mice (Figure 3B). Accordingly, myeloid cell-specific deletion of Serpinb1a in Cebpa\(^{+/+}\)Sb1a\(^{F/F}\) mice reproduced the phenotype of Sb1a\(^{+/-}\) mice characterized by reduced absolute numbers and significantly lower percentage of PMNs in the BM (Figure 4A). As in Sb1a\(^{+/-}\) mice, other cell subsets in the BM were not altered in Cebpa\(^{+/+}\)Sb1a\(^{F/F}\) mice (Figure 3B; Supplementary Figure S1A,B). Numbers of PMNs and other leukocyte subsets in blood as well as other blood parameters were not altered (Figure 4C; Supplementary Figure S1C; Table 1), which is consistent with the phenotype of Sb1a\(^{+/-}\) mice.

PMNs are highly susceptible to granule permeabilization-induced cell death caused by L-leucyl-L-leucine methyl ester (LLME). LLME treatment of PMNs of Cebpa\(^{+/+}\)Sb1a\(^{F/F}\) mice showed reduced survival similar to those of control Cebpa\(^{+/+}\)Sb1a\(^{+/-}\) littermates and of Sb1a\(^{+/-}\) mice (Figure 4D). As shown previously for Sb1a\(^{+/-}\) PMNs (Baumann et al., 2013), caspase inhibition with Q-VD-OPh had no protective effect on cell death of Cebpa\(^{+/+}\)Sb1a\(^{F/F}\) PMNs. Taken together, these data demonstrate that myeloid-specific deletion of Serpinb1a largely replicates the PMN phenotype of constitutive Sb1a\(^{+/-}\) mice.

**Transgenic rescue of Sb1a\(^{+/-}\) neutrophils with human SERPINB1**

Human SERPINB1 cDNA was cloned downstream of the human S100A8 (MRP8) promoter and was injected in the pronucleus of C57BL/6J oocytes. Founder transgenic mice were identified by PCR analysis (Figure 5A). Three of the male founders were crossed with Sb1a\(^{+/-}\) mice. Western blot analysis of PMN lysates revealed that the progeny of founder

**Discussion**

We report that PMNs lacking Serpinb1a protein were successfully generated in mice expressing the cre
models. Failure to generate Serpinb1a protein-null PMNs despite efficient genomic recombination in Lyz2<sup>−/−</sup>Sb1a<sup>F/−</sup> mice is likely due to a combination of factors. First, the floxed Serpinb1a locus was not fully recombed during early stages of granulopoiesis. Second, low levels of Serpinb1a protein may suffice to support PMN survival. Since Serpinb1a transcription is active in HSCs and peaks early in granulopoiesis at the promyelocyte/myelocytes stages (Benarafa et al., 2011), Serpinb1a protein is already accumulating in the cell before the floxed gene is recombed. Thus, sufficient Serpinb1a protein levels may be sustained throughout PMNs’ short life-span and maintain normal PMN levels in the BM of Lyz2<sup>−/−</sup>Sb1a<sup>F/−</sup> mice.

PMNs develop in the BM from hematopoietic stem cells via bipotent granulocyte/macrophage progenitors (GMPs), which can develop into monocyte or PMN lineages. Cebpa is expressed at high levels at the GMP stage, whereas Lyz2 expression peaks later and independently in both granulocyte and monocyte lineages. Cre-mediated recombination using these two cre knock-in models has been widely and successfully used to delete genes in the myeloid compartment. Yet, as we have seen, the timing of cre expression as well as the lineage may be important in achieving effective gene recombination in early stages of granulopoiesis. Recombination efficiency at different stages of hematopoiesis also differs depending on the targeted locus and therefore making the right choice of a cre deleter strain can be difficult and will always require experimental confirmation. Our study highlights that it remains crucial that gene deletion and protein levels are effectively measured particularly when recombination appears to have no effect on the studied phenotype as shown by the absence of BM neutropenia in Lyz2<sup>−/−</sup>Sb1a<sup>F/−</sup> mice. Far from a theoretical question, in studies where protein levels were not verified and showing no phenotype in mice with deleted myeloid cells (Rupe et al., 2005; Kirkland et al., 2012), incomplete protein deletion may have led to overlooking the contribution of the studied proteins in myeloid cells.

We showed here that the extent of the rescue of PMN survival by transgenic expression of human SERPINB1 in Sb1a<sup>F/−</sup> mice was dependent on transgene expression levels. Evaluating the threshold levels of Serpinb1 necessary for cytoprotection is challenging because Serpinb1-protease complexes are processed rapidly into post-complex cleavage forms when proteases are in excess (Cooley et al., 2011). Furthermore, the antibody used in Western blot analysis may react differently with endogenous mouse and transgenic human Serpinb1 as well as with the different complexes. In the Sb1a<sup>F/Tg2</sup> progeny, the hSerpinb1 transgene is relatively weakly expressed and only detectable in
### Table 1: Hematological analysis of whole blood.

<table>
<thead>
<tr>
<th>Genotype</th>
<th>WBC ($\times 10^6$ cells/ml)</th>
<th>RBC ($\times 10^9$ cells/ml)</th>
<th>PLT ($\times 10^6$ cells/ml)</th>
<th>Hemoglobin (g/dl)</th>
<th>Hematocrit (%)</th>
<th>n</th>
</tr>
</thead>
<tbody>
<tr>
<td>$Sb1a^{+/+}$</td>
<td>6.84±3.4</td>
<td>9.57±0.4</td>
<td>1295±248</td>
<td>15.8±0.7</td>
<td>52.7±2.6</td>
<td>8</td>
</tr>
<tr>
<td>$Sb1a^{+/-}$</td>
<td>6.41±1.6</td>
<td>9.38±0.7</td>
<td>1309±160</td>
<td>15.6±1.2</td>
<td>48.2±5.4</td>
<td>7</td>
</tr>
<tr>
<td>$Sb1a^{-/-}$</td>
<td>6.13±2.9</td>
<td>9.57±0.6</td>
<td>1656±129</td>
<td>16.3±0.4</td>
<td>51.2±3.0</td>
<td>4</td>
</tr>
<tr>
<td>Cerca$^{+/+}$</td>
<td>6.06±2.6</td>
<td>9.66±0.7</td>
<td>1479±182</td>
<td>16.2±1.0</td>
<td>50.4±4.3</td>
<td>13</td>
</tr>
<tr>
<td>Cerca$^{+/-}$</td>
<td>6.47±2.4</td>
<td>9.55±0.7</td>
<td>1361±258</td>
<td>15.9±1.2</td>
<td>49.9±5.1</td>
<td>8</td>
</tr>
<tr>
<td>Cerca$^{-/-}$</td>
<td>5.46±0.8</td>
<td>9.49±0.7</td>
<td>1532±187</td>
<td>15.7±1.0</td>
<td>50.3±2.9</td>
<td>5</td>
</tr>
<tr>
<td>Cerca$^{+/-}$</td>
<td>5.69±1.2</td>
<td>9.80±0.6</td>
<td>1348±142</td>
<td>16.1±0.9</td>
<td>51.0±4.4</td>
<td>9</td>
</tr>
</tbody>
</table>

**Figure 5:** Rescue of $Sb1a^{-/-}$ PMN survival by transgenic expression of human SERPINB1.

(A) PCR analysis of genomic DNA of transgenic founders using a single primer pair that recognizes both the human SERPINB1 transgene cDNA (266 bp) and mouse $Serpinb1a$ gene (460 bp, which includes an intronic sequence). (B) Western blot analysis for SERPINB1 and $\beta$-actin of flow-sorted BM PMNs from offsprings of Tg founders 2, 3 and 4. hSerpinb1-protease complex and partly degraded complex are indicated by an arrowhead and an asterisk, respectively. (C) Percentage of PMN numbers in the BM of $Sb1a^{+/+}$ Tg2, $Sb1a^{-/-}$ Tg3 and $Sb1a^{-/-}$ Tg6 mice (**$p<0.01$). (D) Survival of PMNs treated with LLME (100 $\mu$M) in the presence or absence of the caspase inhibitor Q-VD-OPh (50 $\mu$M). Viability was assessed using Annexin V-FITC and 7-AAD staining of Ly-6G$^+$ cells and analyzed by Student’s $t$-test relative to $Sb1a^{-/-}$ PMNs (*$p<0.05$; **$p<0.001$).
complex with proteases. With all the caveats in mind for such a comparison, it suggests that the Tg2 line expresses substantially lower levels than heterozygous Sbta+/− mice, where active mouse Serpinb1a can be detected. Yet, in the Sbta+/−Tg2 mice, we observed a partial rescue of the survival phenotype in vivo and of LLME-induced death in vitro. In the Sbta−/−Tg4 progeny, the transgene was not detectable by Western blot analysis, suggesting very low or no expression and, accordingly, PMN numbers in the BM were as low as in Sbta−/− mice. In the higher expressing transgenic line (Tg3), hSERPINB1 transgene was found in active and complex forms and PMN survival was fully rescued in vitro and in vivo. This new transgenic model will allow us to evaluate the function of the ubiquitously expressed Serpinb1a in non-hematopoietic tissues in the absence of the PMN survival defect in various disease models.

More targeted deletions in tissue or cell subsets could then follow using Sbta+/− mice crossed with other cre-expressing mouse lines. Of note, reporter analysis of Cebpa+/cre mice showed recombination in the liver and lung airway epithelium (Wöfler et al., 2010). It is thus likely that the Sbta+/− locus was recombinated in some non-hematopoietic cells of Cebpa−/cre/Sbta+/− mice. We previously demonstrated that, in BM chimaera, deletion of Sbta in the hematopoietic compartment was necessary and sufficient to reproduce the phenotype of Sbta−/− mice (Baumann et al., 2013). Therefore, effective deletion of Serpinb1a in myeloid cells is undoubtedly the cause of BM neutropenia in Cebpa−/cre/Sbta+/− mice. However, careful scrutiny of Sbta expression in various cell types and time points will be required when using Cebpa−/cre/Sbta+/− mice in systemic disease models. Finally, HSCs of Cebpa−/cre/Sbta+/− mice may be most useful to reconstitute the immune system of irradiated mice to generate myeloid-specific deficiency.

Transgenic mice expressing cre under the hMRP-8 promoter (S100A8) and knock-in models such as neutrophil elastase knock-in mice (Elaneim1(cre/lox)) or Ly6G knock-in (Catchup) mice (Ly6gim262(cre-tdTomato)Arte) are additional models for PMN-specific gene deletion in PMNs (Tkalcevic et al., 2000; Passegué et al., 2004; Hasenberg et al., 2015). These models have reduced targeting of the monocytic lineage than Lyz2 and Cebpa cre knock-in mice used here. Whether Serpinb1a protein-null PMNs can be obtained using these models remains to be tested but is unlikely given the persistence of the protein in PMNs of Lyz2−/cre/Sbfb+/− mice and the small amount of protein rescue needed for mitigating the Sbta−/− phenotype in transgenic mice. For example, deletion of the Fcgr4 gene was complete and specific for PMNs at the genomic level in Catchup mice. While the mice showed a specific phenotype due to gene deletion, FcRIV expression on the PMN surface measured by flow cytometry was only reduced by 50% (Hasenberg et al., 2015). Experimental approaches using cre-mediated recombination in PMNs thus remain challenging in choosing the right cre-expressing model(s) and in the interpretation of the data. In addition to time and resources to generate the mice, it requires specific attention to the target gene expression pattern, protein stability and functional protein threshold to choose the right cre-expressing model(s) and to draw appropriate conclusions.

In summary, we showed that the survival of PMNs depends on a threshold level of Serpinb1 below which serine protease activity is not controlled, leading to cell death. These findings are consistent with the mode of action of Serpinb1 as a stoichiometric inhibitor of neutrophil proteases. Our study further supports the notion that intracellular serpins such as clade B serpins in vertebrates and serpins of Caenorhabditis elegans have a fundamental cytoprotective function (Bird, 1999; Zhang et al., 2006; Luke et al., 2007; Tan et al., 2013; Bird et al., 2014). We have previously demonstrated that BM neutropenia of Sbta−/− mice is dependent on cathepsin G in vivo (Baumann et al., 2013). In addition, Serpinb1 prevents spontaneous PMN apoptosis by inhibiting proteinase-3-mediated cleavage and activation of caspase-3 (Loison et al., 2014). PMNs are exquisitely sensitive to death after granule leakage induced by LLME treatment and cathepsin G is required for this caspase-independent cell death pathway that is critically regulated by Serpinb1 (Baumann et al., 2013). Similarly, Serpinb9 protects cytotoxic lymphocytes against granzyme B-mediated death following granule leakage induced by LLME treatment or by T cell activation (Bird et al., 2014). Serpinb6a is another intracellular serpin inhibitor of cathepsin G that is expressed in PMNs and may contribute to the protease shield against granule permeability-induced cell death. Ongoing studies using multiple targeting of the large locus of clade B serpin loci on mouse chromosome 13 will determine the relative contributions of Serpinb1a, Serpinb6a, Serpinb9 and additional understudied serpin paralogs in cellular homeostasis. The models described here will provide important tools for these studies.

Materials and methods

Ethics statement

All animal studies were approved by the Cantonal Veterinary Office of the canton of Bern and conducted in accordance with the Swiss federal legislation on animal welfare.
Mouse models for conditional deletion of Serpinb1a

Serpinb1a<sup>tm1.1Cben</sup> mice were generated in 129S6/SvEvTac (129S6) background (Benarafa et al., 2007) and backcrossed into C57BL/6J background (Benarafa et al., 2011). The latter were used in this study. Serpinb1a<sup>tm2(flox)Cre</sup> mice were generated in parallel with Sbta<sup>Tm1.2(flox)Cben</sup> mice. Briefly, 129S6/W4 ES cells (Taconic) were targeted by homologous recombination with a linearized plasmid described previously (Benarafa, 2011). Homologous recombinant clones with 3-loxP sites were transiently transfected with Cre recombinase to excise the floxed CMV-HYG/TK positive/negative selection cassette. Cells were further selected with gancyclovir to eliminate the clones where the deletion of the selection cassette did not occur. While most clones tested had recombined the first and third loxP sites, the clones where the deletion of the selection cassette did not occur. Serpinb1atm1.1Cben was used to excise the floxed CMV-HYG/TK positive/negative selection described previously (Benarafa, 2011). Homologous recombinant targeted by homologous recombination with a linearized plasmid Serpinb1atm1.1Cben that recombined the second and third loxP sites, leaving an allele Serpinb1a<sup>tm1.2(flox)Cben</sup> on a C57BL/6J background (Benarafa et al., 2011). The latter was used in this study.

Western bloting

Sorted cells were washed and lysed (10<sup>7</sup>/mL) in RIPA buffer with protease inhibitor cocktail (Roche). Lysates were resolved by SDS-PAGE under reducing conditions and immunoblotted using rabbit antiserum to human SERPINB1 provided by ERO (Rees et al., 1999). Blots were stripped and reblotted with antibodies mentioned above using a FACs Aria II sorter (BD Biosciences) at the flow cytometry core facility of the Department of Clinical Research of the University of Bern.

Cell death induced by granule permeabilization

BM cells were cultured in DMEM (4 mm L-Glut, 25 mm D-Glucose, 1 mm sodium pyruvate) containing 1% FCS and 1% penicillin/streptomycin at 1.0 × 10<sup>6</sup> cells/ml in the presence or absence of the pan-caspase inhibitor Q-VD-OPh (SM Biochemicals LLC) or LLME (G-2550; Bachem). Cells were harvested and viability was assessed using annexin V–fluorescein isothiocyanate (FITC) and 7-aminoactinomycin D (7AAD) and measured at the FACScalibur flow cytometer as above. Flow cytometry data was analyzed using FlowJo (FlowJo LLC). Flow sorting of PMNs, B cells and myelocytes was performed on single-cell suspensions of BM leukocytes stained with antibodies mentioned above using a FACs Aria II sorter (BD Biosciences) at the flow cytometry core facility of the Department of Clinical Research of the University of Bern.

Statistical analysis

Leukocyte subset analysis was performed using Mann-Whitney U-test or Student’s t-test with GraphPad Prism Mac 4.0c software (GraphPad, San Diego, CA, USA). A p Value < 0.05 was considered statistically significant.

Acknowledgments: We thank Elisabeth Frei and Stephan Hirschi for excellent technical assistance. We acknowledge Albert Witt for pronucleus microinjection, Lina Du for ES cell injection and Bernadette Nyfeler for cell sorting. We thank the ZEMB and DKF animal caretaker teams for dedicated attention and husbandry. This study was supported by grants from the Swiss National Science Foundation.
References


Supplemental Material: The online version of this article (DOI: 10.1515/hsz-2016-0132) offers supplementary material, available to authorized users.